Literature DB >> 23204551

Targeting monocytes/macrophages in the treatment of rheumatoid arthritis.

Jean-Luc Davignon1, Myriam Hayder, Michel Baron, Jean-Frédéric Boyer, Arnaud Constantin, Florence Apparailly, Rémy Poupot, Alain Cantagrel.   

Abstract

Biotherapies have revolutionized the treatment of RA. However, much work is needed to understand all the mechanisms of these biotherapies, and alternatives are needed to circumvent adverse effects and the high cost of these long-lasting treatments. In this article we outline some of the approaches we have used to target monocytes/macrophages as major components of inflammation and bone homeostasis. We also discuss how anti-TNF-α antibodies target monocytes/macrophages in the complex mechanisms contributing to inhibition of inflammation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23204551     DOI: 10.1093/rheumatology/kes304

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  83 in total

1.  Mannosylated poly(beta-amino esters) for targeted antigen presenting cell immune modulation.

Authors:  Charles H Jones; Mingfu Chen; Anitha Ravikrishnan; Ryan Reddinger; Guojian Zhang; Anders P Hakansson; Blaine A Pfeifer
Journal:  Biomaterials       Date:  2014-10-22       Impact factor: 12.479

2.  The signaling adaptor TRAF1 negatively regulates Toll-like receptor signaling and this underlies its role in rheumatic disease.

Authors:  Ali A Abdul-Sater; Maria I Edilova; Derek L Clouthier; Achire Mbanwi; Elisabeth Kremmer; Tania H Watts
Journal:  Nat Immunol       Date:  2016-11-28       Impact factor: 25.606

Review 3.  Macrophages and skeletal health.

Authors:  Megan N Michalski; Laurie K McCauley
Journal:  Pharmacol Ther       Date:  2017-02-07       Impact factor: 12.310

Review 4.  The role of tissue resident cells in neutrophil recruitment.

Authors:  Nancy D Kim; Andrew D Luster
Journal:  Trends Immunol       Date:  2015-08-18       Impact factor: 16.687

5.  Anti-Inflammatory Effects and Joint Protection in Collagen-Induced Arthritis after Treatment with IQ-1S, a Selective c-Jun N-Terminal Kinase Inhibitor.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Deepa Hammaker; Irina Kochetkova; Andrei I Khlebnikov; Sergey A Lyakhov; Gary S Firestein; Mark T Quinn
Journal:  J Pharmacol Exp Ther       Date:  2015-03-17       Impact factor: 4.030

6.  Monocyte/Macrophage Abnormalities Specific to Rheumatoid Arthritis Are Linked to miR-155 and Are Differentially Modulated by Different TNF Inhibitors.

Authors:  Audrey Paoletti; Julien Rohmer; Bineta Ly; Juliette Pascaud; Elodie Rivière; Raphaele Seror; Benoit Le Goff; Gaetane Nocturne; Xavier Mariette
Journal:  J Immunol       Date:  2019-09-04       Impact factor: 5.422

7.  Innate immunity sensors participating in pathophysiology of joint diseases: a brief overview.

Authors:  Jiri Gallo; Milan Raska; Yrjo T Konttinen; Christophe Nich; Stuart B Goodman
Journal:  J Long Term Eff Med Implants       Date:  2014

8.  Antiinflammatory Activity of a Novel Folic Acid Targeted Conjugate of the mTOR Inhibitor Everolimus.

Authors:  Yingjuan Lu; Nikki Parker; Paul J Kleindl; Vicky A Cross; Kristin Wollak; Elaine Westrick; Torian W Stinnette; Mark A Gehrke; Kevin Wang; Hari Krishna R Santhapuram; Fei You; Spencer J Hahn; Jeremy F Vaughn; Patrick J Klein; Iontcho R Vlahov; Philip S Low; Christopher P Leamon
Journal:  Mol Med       Date:  2015-07-08       Impact factor: 6.354

9.  The Physiological Role of Tumor Necrosis Factor in Human Immunity and Its Potential Implications in Spinal Manipulative Therapy: A Narrative Literature Review.

Authors:  Liang Zhang; Chao Hua Yao
Journal:  J Chiropr Med       Date:  2016-05-26

10.  Imatinib inhibits CSF1R that stimulates proliferation of rheumatoid arthritis fibroblast-like synoviocytes.

Authors:  X Hu; J Tang; X Hu; P Bao; J Pan; Y Ou; W Deng; Y Liang
Journal:  Clin Exp Immunol       Date:  2018-10-23       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.